Safety of chidamide plus rituximab in elderly patients with relapsed or refractory B-cell lymphoma in China: a multicenter, single-arm, phase II study

BACKGROUND: Patients over 65 years old with diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) relapse or being refractory to rituximab-associated chemotherapy have limited treatment options. Chidamide has the ability to enhance the sensitivity of rituximab-resistant tumors in vivo ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xinrui, Wang, Huaqing, Sun, Xiuhua, Su, Liping, Liu, Fengting, Zhao, Ke, Xu, Liye, Wu, Shaohua, Song, Teng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8756245/
https://www.ncbi.nlm.nih.gov/pubmed/35071463
http://dx.doi.org/10.21037/atm-21-6019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8756245/
https://www.ncbi.nlm.nih.gov/pubmed/35071463
http://dx.doi.org/10.21037/atm-21-6019

Ejemplares similares